Bamco Inc. NY Invests $980,000 in CVS Health Corporation $CVS

Bamco Inc. NY purchased a new stake in CVS Health Corporation (NYSE:CVS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,000 shares of the pharmacy operator’s stock, valued at approximately $980,000.

Several other hedge funds have also added to or reduced their stakes in CVS. Harbor Capital Advisors Inc. grew its stake in CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 142 shares during the last quarter. Corundum Trust Company INC acquired a new stake in CVS Health during the third quarter worth approximately $29,000. Front Row Advisors LLC boosted its holdings in shares of CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 371 shares during the period. Twin Peaks Wealth Advisors LLC acquired a new position in shares of CVS Health in the second quarter valued at approximately $36,000. Finally, SOA Wealth Advisors LLC. increased its stake in shares of CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

CVS Health stock opened at $75.81 on Tuesday. The stock’s fifty day moving average price is $78.08 and its two-hundred day moving average price is $77.85. The firm has a market cap of $96.45 billion, a PE ratio of 54.94, a price-to-earnings-growth ratio of 0.79 and a beta of 0.49. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same period in the prior year, the firm posted $1.19 EPS. CVS Health’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, research analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio is presently 192.75%.

Analysts Set New Price Targets

Several research firms recently issued reports on CVS. Robert W. Baird boosted their price target on CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Wolfe Research lowered their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Royal Bank Of Canada reissued an “outperform” rating on shares of CVS Health in a research report on Thursday, December 4th. Morgan Stanley upped their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and a consensus price target of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.